QUALCOMM INC/DE — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that QUALCOMM INC/DE filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 28, 2025 | $44.28B | Nov 5, 2025 |
| FY2025 | Sep 29, 2024 | $38.96B | Nov 5, 2025 |
| FY2025 | Sep 24, 2023 | $35.82B | Nov 5, 2025 |
| FY2024 | Sep 25, 2022 | $44.20B | Nov 6, 2024 |
| FY2023 | Sep 26, 2021 | $33.57B | Nov 1, 2023 |
| FY2020 | Sep 27, 2020 | $8.35B | Nov 4, 2020 |
| FY2020 | Jun 28, 2020 | $4.89B | Nov 4, 2020 |
| FY2020 | Mar 29, 2020 | $5.22B | Nov 4, 2020 |
| FY2020 | Dec 29, 2019 | $5.08B | Nov 4, 2020 |
| FY2020 | Sep 29, 2019 | $4.81B | Nov 4, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 28, 2025 | $5.54B | Nov 5, 2025 |
| FY2025 | Sep 29, 2024 | $10.14B | Nov 5, 2025 |
| FY2025 | Sep 24, 2023 | $7.23B | Nov 5, 2025 |
| FY2024 | Sep 25, 2022 | $12.94B | Nov 6, 2024 |
| FY2023 | Sep 26, 2021 | $9.04B | Nov 1, 2023 |
| FY2022 | Sep 27, 2020 | $5.20B | Nov 2, 2022 |
| FY2021 | Sep 29, 2019 | $4.39B | Nov 3, 2021 |
| FY2020 | Sep 30, 2018 | ($4.96B) | Nov 4, 2020 |
| FY2018 | Sep 24, 2017 | $168.00M | Nov 7, 2018 |
| FY2018 | Jun 25, 2017 | $866.00M | Nov 7, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 28, 2025 | $12.36B | Nov 5, 2025 |
| FY2025 | Sep 29, 2024 | $10.07B | Nov 5, 2025 |
| FY2025 | Sep 24, 2023 | $7.79B | Nov 5, 2025 |
| FY2024 | Sep 25, 2022 | $15.86B | Nov 6, 2024 |
| FY2023 | Sep 26, 2021 | $9.79B | Nov 1, 2023 |
| FY2020 | Sep 27, 2020 | $3.45B | Nov 4, 2020 |
| FY2020 | Jun 28, 2020 | $782.00M | Nov 4, 2020 |
| FY2020 | Mar 29, 2020 | $991.00M | Nov 4, 2020 |
| FY2020 | Dec 29, 2019 | $1.03B | Nov 4, 2020 |
| FY2020 | Sep 29, 2019 | $701.00M | Nov 4, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 28, 2025 | $9.04B | Nov 5, 2025 |
| FY2025 | Sep 29, 2024 | $8.89B | Nov 5, 2025 |
| FY2025 | Sep 24, 2023 | $8.82B | Nov 5, 2025 |
| FY2024 | Sep 25, 2022 | $8.19B | Nov 6, 2024 |
| FY2023 | Sep 26, 2021 | $7.18B | Nov 1, 2023 |
| FY2022 | Sep 27, 2020 | $5.98B | Nov 2, 2022 |
| FY2021 | Sep 29, 2019 | $5.40B | Nov 3, 2021 |
| FY2020 | Sep 30, 2018 | $5.63B | Nov 4, 2020 |
| FY2019 | Sep 24, 2017 | $5.49B | Nov 6, 2019 |
| FY2018 | Sep 25, 2016 | $5.15B | Nov 7, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 28, 2025 | $3.11B | Nov 5, 2025 |
| FY2025 | Sep 29, 2024 | $2.76B | Nov 5, 2025 |
| FY2025 | Sep 24, 2023 | $2.48B | Nov 5, 2025 |
| FY2024 | Sep 25, 2022 | $2.57B | Nov 6, 2024 |
| FY2023 | Sep 26, 2021 | $2.34B | Nov 1, 2023 |
| FY2022 | Sep 27, 2020 | $2.07B | Nov 2, 2022 |
| FY2021 | Sep 29, 2019 | $2.20B | Nov 3, 2021 |
| FY2020 | Sep 30, 2018 | $2.99B | Nov 4, 2020 |
| FY2019 | Sep 24, 2017 | $2.66B | Nov 6, 2019 |
| FY2018 | Sep 25, 2016 | $2.39B | Nov 7, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 28, 2025 | $14.01B | Nov 5, 2025 |
| FY2025 | Sep 29, 2024 | $12.20B | Nov 5, 2025 |
| FY2025 | Sep 24, 2023 | $11.30B | Nov 5, 2025 |
| FY2024 | Sep 25, 2022 | $9.10B | Nov 6, 2024 |
| FY2023 | Sep 26, 2021 | $10.54B | Nov 1, 2023 |
| FY2022 | Sep 27, 2020 | $5.81B | Nov 2, 2022 |
| FY2021 | Sep 29, 2019 | $7.29B | Nov 3, 2021 |
| FY2020 | Sep 30, 2018 | $3.91B | Nov 4, 2020 |
| FY2019 | Sep 24, 2017 | $5.00B | Nov 6, 2019 |
| FY2018 | Sep 25, 2016 | $7.63B | Nov 7, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 28, 2025 | $50.14B | Nov 5, 2025 |
| FY2025 | Sep 29, 2024 | $55.15B | Nov 5, 2025 |
| FY2024 | Sep 24, 2023 | $51.04B | Nov 6, 2024 |
| FY2023 | Sep 25, 2022 | $49.01B | Nov 1, 2023 |
| FY2022 | Sep 26, 2021 | $41.24B | Nov 2, 2022 |
| FY2021 | Sep 27, 2020 | $35.59B | Nov 3, 2021 |
| FY2020 | Sep 29, 2019 | $32.96B | Nov 4, 2020 |
| FY2020 | Sep 30, 2018 | $32.72B | Nov 4, 2020 |
| FY2019 | Sep 24, 2017 | $65.50B | Nov 6, 2019 |
| FY2018 | Sep 25, 2016 | $52.36B | Nov 7, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 28, 2025 | $28.94B | Nov 5, 2025 |
| FY2025 | Sep 29, 2024 | $28.88B | Nov 5, 2025 |
| FY2024 | Sep 24, 2023 | $29.46B | Nov 6, 2024 |
| FY2023 | Sep 25, 2022 | $31.00B | Nov 1, 2023 |
| FY2022 | Sep 26, 2021 | $31.29B | Nov 2, 2022 |
| FY2021 | Sep 27, 2020 | $29.52B | Nov 3, 2021 |
| FY2020 | Sep 29, 2019 | $28.05B | Nov 4, 2020 |
| FY2019 | Sep 30, 2018 | $31.91B | Nov 6, 2019 |
| FY2018 | Sep 24, 2017 | $34.74B | Nov 7, 2018 |
| FY2017 | Sep 25, 2016 | $20.59B | Nov 1, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Sep 29, 2019 | $4.91B | Nov 6, 2019 |
| FY2019 | Sep 30, 2018 | $807.00M | Nov 6, 2019 |
| FY2019 | Sep 24, 2017 | $30.73B | Nov 6, 2019 |
| FY2017 | Sep 25, 2016 | $31.78B | Nov 1, 2017 |
| FY2016 | Sep 27, 2015 | $31.42B | Nov 2, 2016 |
| FY2015 | Sep 28, 2014 | $39.17B | Nov 4, 2015 |
| FY2014 | Sep 29, 2013 | $36.09B | Nov 5, 2014 |
| FY2013 | Sep 30, 2012 | $33.52B | Nov 6, 2013 |
| FY2012 | Sep 25, 2011 | $26.95B | Nov 7, 2012 |
| FY2011 | Sep 26, 2010 | $20.86B | Nov 2, 2011 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 28, 2025 | $11.36B | Nov 5, 2025 |
| FY2025 | Sep 29, 2024 | $10.80B | Nov 5, 2025 |
| FY2025 | Sep 24, 2023 | $10.64B | Nov 5, 2025 |
| FY2024 | Sep 25, 2022 | $10.51B | Nov 6, 2024 |
| FY2023 | Sep 26, 2021 | $7.25B | Nov 1, 2023 |
| FY2022 | Sep 27, 2020 | $6.32B | Nov 2, 2022 |
| FY2021 | Sep 29, 2019 | $6.28B | Nov 3, 2021 |
| FY2020 | Sep 30, 2018 | $6.50B | Nov 4, 2020 |
| FY2019 | Sep 24, 2017 | $6.62B | Nov 6, 2019 |
| FY2018 | Sep 25, 2016 | $5.68B | Nov 7, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 28, 2025 | $20.65B | Nov 5, 2025 |
| FY2025 | Sep 29, 2024 | $25.69B | Nov 5, 2025 |
| FY2024 | Sep 24, 2023 | $20.73B | Nov 6, 2024 |
| FY2023 | Sep 25, 2022 | $17.84B | Nov 1, 2023 |
| FY2022 | Sep 26, 2021 | $9.82B | Nov 2, 2022 |
| FY2021 | Sep 27, 2020 | $5.28B | Nov 3, 2021 |
| FY2020 | Sep 29, 2019 | $4.47B | Nov 4, 2020 |
| FY2019 | Oct 1, 2018 | $1.38B | Nov 6, 2019 |
| FY2019 | Sep 30, 2018 | $542.00M | Nov 6, 2019 |
| FY2018 | Sep 24, 2017 | $30.09B | Nov 7, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 28, 2025 | $5.52B | Nov 5, 2025 |
| FY2025 | Sep 29, 2024 | $7.85B | Nov 5, 2025 |
| FY2024 | Sep 24, 2023 | $8.45B | Nov 6, 2024 |
| FY2023 | Sep 25, 2022 | $2.77B | Nov 1, 2023 |
| FY2022 | Sep 26, 2021 | $7.12B | Nov 2, 2022 |
| FY2021 | Sep 27, 2020 | $6.71B | Nov 3, 2021 |
| FY2020 | Sep 29, 2019 | $11.84B | Nov 4, 2020 |
| FY2019 | Sep 30, 2018 | $11.78B | Nov 6, 2019 |
| FY2019 | Sep 24, 2017 | $35.03B | Nov 6, 2019 |
| FY2018 | Sep 25, 2016 | $5.95B | Nov 7, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 28, 2025 | $14.81B | Nov 5, 2025 |
| FY2025 | Sep 29, 2024 | $13.27B | Nov 5, 2025 |
| FY2024 | Sep 24, 2023 | $14.48B | Nov 6, 2024 |
| FY2023 | Sep 25, 2022 | $13.54B | Nov 1, 2023 |
| FY2022 | Sep 26, 2021 | $13.70B | Nov 2, 2022 |
| FY2021 | Sep 27, 2020 | $15.23B | Nov 3, 2021 |
| FY2020 | Sep 29, 2019 | $13.44B | Nov 4, 2020 |
| FY2019 | Sep 30, 2018 | $15.37B | Nov 6, 2019 |
| FY2018 | Sep 24, 2017 | $19.40B | Nov 7, 2018 |
| FY2017 | Sep 25, 2016 | $10.01B | Nov 1, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 28, 2025 | 5 | Nov 5, 2025 |
| FY2025 | Sep 29, 2024 | 9 | Nov 5, 2025 |
| FY2025 | Sep 24, 2023 | 6 | Nov 5, 2025 |
| FY2024 | Sep 25, 2022 | 11 | Nov 6, 2024 |
| FY2023 | Sep 26, 2021 | 7 | Nov 1, 2023 |
| FY2020 | Sep 27, 2020 | 2 | Nov 4, 2020 |
| FY2020 | Jun 28, 2020 | 0 | Nov 4, 2020 |
| FY2020 | Mar 29, 2020 | 0 | Nov 4, 2020 |
| FY2020 | Dec 29, 2019 | 0 | Nov 4, 2020 |
| FY2020 | Sep 29, 2019 | 0 | Nov 4, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 28, 2025 | 5 | Nov 5, 2025 |
| FY2025 | Sep 29, 2024 | 8 | Nov 5, 2025 |
| FY2025 | Sep 24, 2023 | 6 | Nov 5, 2025 |
| FY2024 | Sep 25, 2022 | 11 | Nov 6, 2024 |
| FY2023 | Sep 26, 2021 | 7 | Nov 1, 2023 |
| FY2020 | Sep 27, 2020 | 2 | Nov 4, 2020 |
| FY2020 | Jun 28, 2020 | 0 | Nov 4, 2020 |
| FY2020 | Mar 29, 2020 | 0 | Nov 4, 2020 |
| FY2020 | Dec 29, 2019 | 0 | Nov 4, 2020 |
| FY2020 | Sep 29, 2019 | 0 | Nov 4, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 28, 2025 | 1.07B | Nov 5, 2025 |
| FY2025 | Sep 29, 2024 | 1.11B | Nov 5, 2025 |
| FY2024 | Sep 24, 2023 | 1.11B | Nov 6, 2024 |
| FY2023 | Sep 25, 2022 | 1.12B | Nov 1, 2023 |
| FY2022 | Sep 26, 2021 | 1.13B | Nov 2, 2022 |
| FY2021 | Sep 27, 2020 | 1.13B | Nov 3, 2021 |
| FY2020 | Sep 29, 2019 | 1.15B | Nov 4, 2020 |
| FY2019 | Sep 30, 2018 | 1.22B | Nov 6, 2019 |
| FY2018 | Sep 24, 2017 | 1.47B | Nov 7, 2018 |
| FY2018 | Sep 25, 2016 | 1.48B | Nov 7, 2018 |